Conclusion
In conclusion, we provide a case of pembrolizumab-induced
cardiomyopathy, a rare treatment-associated side effect with no proven
cure. Reintroducing ICI treatment after efficient management of
myocarditis is under study worldwide as it is one of the most promising
medications for improving survival in patients with NSCLC and other
solid tumors. However, more research is needed to find the best patient
features for reintroducing ICI treatment safely while reducing the risk
of recurrent myocarditis.